Drug intelligence / Profile preview

RM 06

Development stage: Preclinical
Lead developer: Azurity Pharmaceuticals
Modality: Small Molecules

Overview

**RM 06** is an immunomodulator featuring a peptidyl hypoxanthine structure. It significantly reduces the number of lung metastases from B16 melanoma cells in mouse models, indicating potential anti-metastatic activity in cancer. Azurity Pharmaceuticals (formerly CutisPharma), in collaboration with Dr. Reddy's Laboratories, is developing it for gastrointestinal disorders, though detailed clinical data and mechanism specifics remain limited.[1][5]

Beyond the preview

Go deeper on RM 06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RM 06.

Explore the full profile